arrow
Y

Yazeed Sawalha

The Ohio State University
H指数:12
被引数:601

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study

成人淋巴瘤患者中血浆神经丝轻链纵向变化与患者报告结局作为长春新碱相关周围神经病变的补充标记:一项队列研究

2026-09-130
OA
Spatial tissue analysis of secondary sarcoma following CAR T cell therapy for B cell lymphoma

B细胞淋巴瘤CAR T细胞疗法后继发性肉瘤的空间组织分析

2026-07-010
PRE
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab

复发/难治性侵袭性B细胞淋巴瘤接受epcoritamab治疗后的预后因素和生存结局

2026-06-090
OAAI
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

中枢神经系统淋巴瘤患者中CD3xCD20双特异性抗体的临床疗效

2026-05-220
OAAI
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexate

非霍奇金淋巴瘤患者接受大剂量甲氨蝶呤治疗时与末相甲氨蝶呤清除率相关的临床特征

2026-02-010
PRE
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma

二线CD19 CAR-T治疗与铂类挽救疗法及自体干细胞移植治疗原发纵隔B细胞淋巴瘤的比较

2026-01-010
OA
A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation

一项关于Duvelisib与Nivolumab联合治疗弥漫性大B细胞淋巴瘤、转化性滤泡性淋巴瘤和Richter转化的I期研究

2025-12-010
PRE
Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis

复发/难治性淋巴浆细胞样淋巴瘤/华氏巨球蛋白血症患者接受维奈克拉治疗后的结局:一项多中心回顾性分析

2025-04-150
OA
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies

血液恶性肿瘤患者接受CAR T细胞疗法后的第二原发恶性肿瘤

2025-03-180
OA
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma

新诊断的原发性弥漫性大B细胞淋巴瘤患者中,循环淋巴瘤细胞在诊断时对预后的影响

2025-01-050
OA
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
2024-11-141
OAAI
Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

在≤70岁套细胞淋巴瘤患者强化一线化疗免疫治疗中添加或替代Acalabrutinib:ECOG-ACRIN EA4181三臂随机Ⅱ期协作组试验的结果

BLOOD
IF23.1
2024-11-051
PRE
Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

CAR-T疗法后疾病进展的复发或难治性套细胞淋巴瘤患者的治疗方案与结局:一项多中心分析

BLOOD
IF23.1
2024-11-050
PRE
Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

急性髓系白血病患者伴自身免疫性疾病史的基因分型与生存分析

BLOOD
IF23.1
2024-11-050
PRE
A Phase I/II Study of Tazemetostat Combined with Abbreviated Rituximab/Bendamustine Therapy for High Tumor Burden Follicular Lymphoma in Frontline Treatment: A Big Ten Cancer Research Consortium Study

一项Tazemetostat联合简化利妥昔单抗/苯达莫司汀方案治疗一线高肿瘤负荷滤泡性淋巴瘤的I/II期研究:一项Big Ten癌症研究联盟研究

BLOOD
IF23.1
2024-11-050
PRE
Postinfusion PD-1+CD8+CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma
2024-06-131
OAAI
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
2023-12-135
OAAI